Monthly Archives: June 2021

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The details are as follows:

The fireside chat will be webcast live and available thereafter using the link provided above.

About Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as may, should, could, intend, estimate, plan, anticipate, expect, believe or continue, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding enhanced liquidity, the value of additional capital markets exposure, access to institutional and retail investors, the Companys new strategic brand messaging campaign, and psychedelic drug development programs to potentially treat mental health disorders. There are numerous risks and uncertainties that could cause actual results and Cybins plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes no medical, treatment or health benefit claims about Cybins proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceutical products. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybins performance and operations.

The NEO Exchange has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

Excerpt from:

Cybin to Participate in Grizzle Psychedelics Con on June 28th - Business Wire

25 June 2021

Seyfarth Shaw LLP

To print this article, all you need is to be registered or login on Mondaq.com.

Seyfarth Synopsis: On June 1, 2021, theCalifornia State Senate passed Senate Bill 519 which calls for thelegalization for non-commercial use of specific psychedelics. ThisBill is the newest among the growing list of legalization effortsof psychedelics, this being a major momentum shift.

In the most recent news of the ongoing modern psychedelicrevolution, the California State Senate approved Senate Bill 519 on June 1, 2021. This bill,sponsored by Senator Scott Wiener, aims to legalize the possessionand sharing of certain psychedelics. The list includes psilocybin,ketamine, MDMA, LSD, and non-peyote derived mescaline forCalifornians 21 and over. After its passing in the senate, the billnow moves to the Democratically controlled California StateAssembly, and should it pass there it will be sent to GovernorGavin Newsom for his final approval.

This bill is a legalization, not decriminalization effort,making it legal to not only possess and share the listedpsychedelics, but also cultivate naturally occurring psychedelicsfor personal use specifically. This means home grown spores wouldbe free to spread in backyards across California, as the billspecifically allows property owners to possess spores or myceliumproducing mushrooms for personal or social use.

Notably, the bill allows Californians to have the psychedelicsfor "social use," which is defined as "the givingaway or consensual administering of," the covered substances,by someone 21 or older to someone 21 or older. Social sharingincludes but is not limited to group counseling, spiritualguidance, community-based healing, or related services.

However, the bill specifically disallows offering thesesubstances for financial gain, which is defined as the receipt ofmoney or other valuable consideration in exchange for the itembeing shared. This does not apply to reasonable fees forcounseling, spiritual guidance, or related services that areprovided in tandem with both the administering or use of any of thecontrolled substances specifically under the guidance andsupervision of the person providing those services on the premises,and on the premises of the person providing the services.This section in particular may create an interesting carve out foradministering the substances, for a reasonable fee, but only undersupervision of a guide upon their designated premises.

Moreover, the bill calls for the California Department of Healthto convene a working group that will research and makerecommendations to the state legislature on the regulation and useof substances legalized by this bill.

This bill is the latest spore to pop up in the growing networkof psychedelic legislation within the United States. The billspecifically cites other related initiatives in the City of Oakland and City of Santa Cruz as inspiration, as well as Ann Arbor, Michigan; Somerville, Massachusetts; and Cambridge, Massachusetts; which have alldecriminalized possession, use, and propagation of psychedelicplants and fungi. Washington DC has also passed Initiative 81which decriminalized and deprioritized the possession of certainpsychedelics.

With SB 519's passage, the proponents for psychedelicmedical and personal use will land a major win, and the bill mayact as a catalyst for more states to consider psychedeliclegalization, potentially leading to a similar market like that ofthe budding cannabis industry.

The content of this article is intended to provide a generalguide to the subject matter. Specialist advice should be soughtabout your specific circumstances.

POPULAR ARTICLES ON: Cannabis & Hemp from United States

Obhan & Associates

Trademarks Comparative Guide for the jurisdiction of India, check out our comparative guides section to compare across multiple countries

Go here to read the rest:

California State Senate Passes Psychedelic Legalization In Latest Wave Of The New Psychedelic Revolution - Cannabis & Hemp - United States -...

Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded higher by 3.3% on Monday after one analyst initiated bullish coverage of the psychedelics stock.

The Analyst:Maxim analyst Jason McCarthy initiated coverage of MindMed with a Buy rating and $6 price target.

The Thesis:McCarthy said MindMed is well-funded, reasonably valued and has plenty of promising research projects in the works.

MindMed has one of the most diverse pipelines in psychedelics and a partnership with a leading research institution to provide exclusive license to data to support continued expansion, McCarthy wrote in a note.

MindMeds leading research program is Project Lucy, a Phase 2a trial of high-dose (experiential) LSD to treat generalized anxiety disorder (GAD). In addition, MidMed is developing a LSD neutralizer that could potentially help terminate the drugs psychoactive period and potentially reduce the possibility of adverse events.

EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO

MindMed is also researching the potential use of LSD in treating ADHD and pain and testing its 18-MC ibogaine derivative for use in treating opioid addiction.

McCarthy is projecting commercialization of MindMeds MM-120 (LSD) for GAD in the U.S. and Europe in 2026 and is factoring in a 60% risk adjustment. He is also projecting commercialization of MM-290 (low dose LSD) for ADHD in the U.S. and Europe in 2027 with an 80% risk adjustment and MM-110 (18-MC) in the U.S. and Europe in 2025 with a 70% risk adjustment.

The company has about $160 million in cash to fund its research, and potential data readouts on its various programs could serve as bullish catalysts for the stock through the end of 2022, McCarthy said.

Benzingas Take: The psychedelics stock group is a small group of public companies working in a very early stage market that is extremely high risk. However, if psychedelics follow the same long-term trajectory that cannabis has, early investors that are willing to stomach the risk and volatility could generate some spectacular long-term gains.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See more here:

Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics' - Benzinga - Benzinga

MINNEAPOLIS, June 28, 2021 /PRNewswire/ -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS;OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP incubator, today announced that its subsidiary, Resurgent Biosciences ("Resurgent"), has filed for a U.S. patent to create an expansive suite of virtual reality ("VR") applications that can be used by practitioners during psychedelic-based therapies to enhance and guide patients through the experience and potentially create optimized, longer-lasting therapeutic outcomes.

One of the largest unmet needs in the psychedelic space is a scalable platform that will allow medical practitioners to administer psychedelic medicine remotely in a consistent and controlled environment. To address this need, Resurgent is developing a suite of VR applications that will provide customizable environments and programs for psychedelic therapy and the extensive preparation work necessary to optimize therapeutic psychedelic experiences.

"The therapeutic potential of psychedelic medicines at least partially depends on an effective preparation phase to ensure that patients are in the right mindset and in beneficial surroundings in order to create a positive experience, which is often referred to as set and setting," said Chairman and Chief Executive Officer, Kyle Kingsley, M.D. "We believe that VR programs allow practitioners to better prepare and guide patients through their experiences and may optimize therapeutic approaches with psychedelic medicines."

Resurgent has contracted with Cubicle Ninjas, a leading VR development firm in Chicago, to begin work on development of a VR suite for various technology applications for psychedelic therapies. The Cubicle Ninjas team was selected because of their extensive VR development expertise, particularly in the context of health and wellness applications.

Resurgent and Cubicle Ninjas Plan to Begin Developing the Following VR Applications:

The applications will allow for practitioners and patients to customize and adapt VR programs based on individual needs with easy-to-use controls and settings. Resurgent expects to have working prototypes completed by the end of the year.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world. The Company's operations consist primarily of its multi-state cannabis company subsidiary, Vireo Health, and its science and intellectual property incubator, Resurgent Biosciences. The Company manufactures proprietary, branded cannabis products in environmentally friendly facilities, state-of-the-art cultivation sites and distributes its products through its growing network of Green Goods and other retail locations and third-party dispensaries. Its teams of more than 500 employees are focused on the development of differentiated products, driving scientific innovation of plant-based medicines, and developing meaningful intellectual property. Today, the Company is licensed to grow, process, and/or distribute cannabis in eight markets and operates 17 dispensaries across the United States. For more information about Goodness Growth Holdings, please visit http://www.goodnessgrowth.com.

About Cubicle Ninjas

Cubicle Ninjas is a creative marketing agency with over 10 years of success creating brands, products, platforms and experiences that drive connections. The full-service creative design agency was founded to create one-of-a-kind experiences through the union of design and technology. Their world-class design and development teams innovate for Fortune 500, start-ups, non-profits, and mid-sized firms alike, crafting functionally intuitive and emotionally impactful work. For more information about Cubicle Ninjas, please visit http://www.cubicleninjas.com.

Contact Information

Investor Inquiries:

Media Inquiries:

Sam Gibbons

Albe Zakes

Vice President, Investor Relations

Vice President, Corporate Communications

[emailprotected]

[emailprotected]

(612) 314-8995

(267) 221-4800

Forward-Looking Statement Disclosure

This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "plan," "potentially," "potential," "will," "believe," "may," "expects," or variations of such words and phrases. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to current and future economic conditions; risks related to the COVID-19 pandemic; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws in the United States relating to psychedelics and any changes to such laws; operational, regulatory, and other risks; execution of business strategy; difficulty to forecast; conflicts of interest; liquidity and additional financing; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at http://www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results, or otherwise, other than as required by applicable securities laws.

SOURCE Goodness Growth Holdings

https://goodnessgrowth.com

Originally posted here:

Goodness Growth Holdings Subsidiary Resurgent Biosciences Files Patent for Virtual Reality Applications to Facilitate Therapeutic Psychedelic...

Posted on June 25, 2021

DALLAS (WBAP/KLIF)-Governor Greg Abbott signed a bill into law that will allow for the study of psychedelics as a treatment for PTSD in veterans.

Under the new psychedelics law, Texas will study potential benefits and risks of magic mushrooms, ketamine and MDMA- but it will be controlled dosing.

A lot of people think of ketamine as a club drug, which it is, but thats not what theyre talking about when they are using ketamine for depression. Its done in a clinical setting, under medical supervision, the dosing is controlled the supply chain is verified, said Joe Schrank, addiction specialist and program director for The Heavenly Center.

The law is receiving support from veterans groups, including mental health advocacy group VETS. Additionally, days before this bill was signed into law,Gov. Abbott also signed a bill that will expand Texas medical marijuana program.

The more we research, the more we find there are many other options for health and well being.Were in a massive mental health crisis and must be open to all potential options.This is paradoxical to Americas current drug policy but we have to keep in mind the war on drugs has now been a 50 year waste of time and money inflicting harm on the culture. More research should be done, but we shouldnt reject this as a possible help, saysSchrank.

Continue reading here:

New TX Law Allows for Study of Psychedelics as Treatment for Veterans with PTSD - WBAP News/Talk

The psychedelics movement continues to take hold of the Americas, as more jurisdictions continue to decriminalize the substances, research flourishes and big companies go public.

Since Novemberwhen Oregon became the first state to legalize psilocybin therapy and decriminalize all drugs, and Washington, D.C. decriminalized all natural psychedelics a legislator in Florida introduced a bill to legalize psilocybin therapy, three cities in Massachusetts decriminalized psychedelics, and the entire state of California might soon do the same, sharedDoubleBlind co-founder and CEO Shelby Hartman. As reform sweeps the country, and federally-approved psychedelic research plows ahead, we take a moment in this issue to reflect on what were really trying to accomplish. Mental health? Collective, social healing? Or perhaps bothand much more.

DoubleBlind Issue 05 dives deep into what it means to live psychedelically: It provokes questions we may ask ourselves, like who we are and how we move through the world when we are in our deepest moments of clarity.

These questions are coming to the fore. In forcing us inside our homes and insideourselves, the pandemic led many toquestion our values and now we're doing so in the psychedelic community, too. As we hurtle into the future with the toppling of prohibition, decriminalization measures across the country, and the fast pace at which more and more companies are developing psychedelic medicine, now is prime time to investigate the values of the psychedelic space, and how we want to live according to the spirit of these medicines.

In the issue, DoubleBlind explores the future of MDMA godfather Sasha Shulgin's legacy, what happens when psychedelics throw us into spiritual crisisas well as the iconography of Mexican curandera Maria Sabina and what she represents to the psychedelic movement as a whole.

The magazine also features columns by Francoise Bourzat, author of ConsciousnessMedicine

who offers her prayer for the forthcoming psychedelic industry: that sacred medicines are not reduced to medication for mental health as well as from Ismail Ali, a lawyer for MAPS, who makes a poignant case for what spiritual practice, regardless of its origin, might look like when put to work in the world. His column is aptly titled "Islamhuasca."

Find the magazine following this link.

And more from DoubleBlind in Spanish on El Planteo:

Cmo Sobrellevar un Mal Viaje de Psicodlicos

Gua Prctica: Cmo Secar Hongos Psicodlicos

Microdosis de Psicodlicos para la Ansiedad: lo que Debes Saber

Read more:

What It Means To Live 'Psychedelically:' DoubleBlind Mag #05 Dives Deep Into The Topic - Benzinga - Benzinga

TORONTO--(BUSINESS WIRE)--NEO is pleased to welcome Vancouver-based Filament Health Corp. (Filament), an exclusively-natural psychedelic drug discovery and extraction technology company, to the NEO Exchange. Filament began trading today under the symbol FH.

With a robust and innovative IP portfolio, accomplished management team, in-house GMP manufacturing capabilities, and a Health Canada psilocybin Dealers License, Filament is focused on addressing the current mental health crisis.

Listing on NEO, a senior exchange with high governance requirements, helps to establish Filament as a leader in the psychedelics industry, remarked Filament CEO, Benjamin Lightburn. NEO has proven to be a strong and supportive partner to innovative companies like Filament. The capital access made possible by this going-public transaction allows us to further our mission of getting safe, natural psychedelics into the hands of everyone who needs them, as soon as possible.

Investors can trade shares of FH through their usual investment channels, including discount brokerage platforms and full-service dealers.

Filaments debut on the NEO Exchange marks our fifth corporate listing in the psychedelics space, noted Jos Schmitt, President and CEO. Between both of our companies, we share a relentless pursuit of innovation, and NEO is thrilled to welcome a fellow disruptor to our ranks. Filament will benefit from the many advantages of being listed on a Tier 1 stock exchange, including unparalleled service and support, increased access to institutional investors, and enhanced transparency and quality of trading. We look forward to showing the world that NEO is the place to be for industry-defining companies in the innovation economy.

Filaments debut on the NEO Exchange follows other recent issuers in the psychedelics industry including Awakn Life Sciences Corp., Mydecine Innovations Group, Cybin Inc., and MindMed, the worlds first-ever psychedelics company to go public.

NEO is home to more than 140 corporate and ETF listings, and consistently facilitates close to 15% of all Canadian trading volume. Click here for a complete view of all NEO-listed securities.

About the NEO Exchange

The NEO Exchange is Canadas Tier 1 stock exchange for the innovation economy, bringing together investors and capital raisers within a fair, liquid, efficient, and service-oriented environment. Fully operational since June 2015, NEO puts investors first and provides access to trading across all Canadian-listed securities on a level playing field. NEO lists companies and investment products seeking an internationally recognized stock exchange that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data.

Connect with NEO: Website | LinkedIn | Twitter | Instagram | Facebook

About Filament Health Corp.

Filament is an exclusively-natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the worlds mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology and commercialization, utilizing its intellectual property portfolio, in-house good manufacturing practices capabilities, and a Health Canada psilocybin Dealers License. Filament is headquartered in Vancouver, British Columbia.

Connect with Filament: Website | LinkedIn | Twitter | Instagram | Newsletter

Read more:

Exclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange - Business Wire

June22, 20214 min read

Shares were priced at $15, the high end of the projected range, with 15 million shares changing hands. All the newly public shares were offered by the company, rather than other individual or institutional owners.

The company now has a market capitalization of $3.1 billion, placing it in mid-cap territory.

The stock climbed as high as $22.91 in the session, closing at $19.45. Trading above the IPO price is a good indication of demand for a new issue.

Atai focuses on the use of psychedelics to treat mental health conditions. Its considered a clinical-stage biotech. The company does not yet have regulators OK to move forward with treatments.

According to a company press release, Atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics. Atai is headquartered in Berlin, with offices in New York and London.

Currently, the treatments and molecules the company is developing are in Phase II clinical trials.

Atais public debut follows that of two other biotechs specializing in psychedelics. New York-based Mind Medicine (NASDAQ: MNMD), which went public in April, and U.K.-based Compass Pathways (NASDAQ: CMPS), which made its debut in September.

Atia owns about a quarter of outstanding shares of Compass Pathways.

All these young companies are developing treatments using LSD and MDMA derivatives, in addition to the psychedelic mushroom compound, psilocybin, to treat mental illnesses such as anxiety, schizophrenia, depression and other conditions. These new meds also have promise for treating addiction.

Atai has 10 therapeutic treatments in the pipeline.

Compass Pathways, the first of the three psychedelic-focused companies to go public, is focused on development for untreatable depression using psilocybin mushrooms.

Its become well known that the pandemic accelerated mental health problems around the world. While the pharmaceutical industry has been developing antidepressants and other medications for decades, many patients find the existing meds dont work.

Thats where the promise of mushrooms and the other psychedelics comes into play.

Compass treatments are currently in Phase II trials, with results expected to be released later this year.

As with cannabis, medicinal use of psychedelics has been hamstrung by governmental restrictions. However, major universities, such as the University of California, Yale and Johns Hopkins are conducting research into the role of psychedelics in psychological treatment.

For example, studies have shown that MDMA, more commonly known as ecstasy or Molly, has potential for treating post-traumatic stress disorder.

Although the industry shows a great deal of potential, these stocks harken back to the early days of publicly traded cannabis companies. These are small companies, with little trading history, scant analyst coverage and little institutional investment.

For example, at Compass Pathways, insiders own 31% of shares, with mutual funds holding just 13%. The number of funds owning shares held steady at 29 for the quarters ending in December in March. Thats not so surprising, given that the stock has a market cap of just $1.43 billion and is so new to the public markets.

Compass is not yet a buyable stock, as its still finding its way as a newly public company. After its IPO, the stock rallied to a high of $61.69 on December 14, then pulled into a new correction. It hit resistance at $58.62 in February, and has been etching a base since then.

Until theres a definitive uptrend, the stock remains one to watch, not buy.

As for Mind Medicine, its forming its first post-IPO base and also merits watching. None of the three newly public psychedelic companies are expected to show any earnings in the foreseeable future, so all of these would be speculative buys at this time.

Featured Article: Options Trading - What is a Straddle?

Read the original here:

Atai Goes Public With Promising New Mental-Health Treatments Based On Psychedelics - Entrepreneur